A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.

@article{Guerra2012AHP,
  title={A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.},
  author={Anna Guerra and Laura Fugazzola and Vincenzo Marotta and Massimo Cirillo and Stefania Patrizia Sonia Rossi and Valentina Cirello and Irene Forno and Tania Moccia and Alfredo Budillon and Mario Vitale},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2012},
  volume={97 7},
  pages={
          2333-40
        }
}
CONTEXT BRAF(V600E) is considered a negative prognostic marker in papillary thyroid carcinoma (PTC), but unexplained conflicting results are present in the literature. In light of the new finding that most PTC consist of a mixture of tumor cells with wild-type and mutant BRAF, we examined the associations between the percentage of BRAF(V600E) alleles and both the clinicopathological parameters at time of diagnosis and the disease outcome in a large series of PTCs. STUDY DESIGN Tumors from 168… 
View on PubMed
academic.oup.com
115 Citations
Highly Influential Citations
8
Background Citations
40
Methods Citations
6
Results Citations
9

Figures and Tables from this paper

115 Citations

Citation Type

Citation Type

Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.
TLDR
In a population with prevalent BRAF mutations, quantitative analysis of the BRAF mutation could provide additional information regarding tumour behaviour, which is not reflected by qualitative analysis, but prospective studies are needed before the mutated allele percentage can be considered as a prognostic factor.
The ratio of BRAFV600E alleles can be used to assess the biological behavior of papillary thyroid carcinoma
TLDR
The ratio of BRAFV600E alleles can reliably reflect the biological behavior of PTC, making it a molecular-based stratification index of recurrence risk and has the potential to guide the clinical diagnosis and treatment of P TC.
Clinical implications of the extent of BRAFV600E alleles in patients with papillary thyroid carcinoma.
Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
TLDR
The occurrence and percentage of the BRAF V600E mutated allele was not preferentially associated with the development of metastases and the average mutated allele percentage decreased as the tumor progresses from the primary site to the lymph node metastatic sites.
BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.
TLDR
The findings from this large meta-analysis definitively demonstrate that BRAFV600E-mutation-positive PTMC are more likely to manifest with aggressive clinicopathological characteristics and in appropriate clinical settings testing for the BRAFv600E mutation is likely to be useful in assisting the risk stratification and management of PTMC.
The BRAF V600E mutation predicts poor survival outcome in patients with papillary thyroid carcinoma: a meta analysis.
TLDR
The poor prognosis predicted role of BRAf V600E mutation in PTC was certified from the current meta-analysis and the BRAF V600e mutation may be used as a prognostic predictor of patients with PTC.
Subclonality for BRAF Mutation in Papillary Thyroid Carcinoma Is Associated With Earlier Disease Stage.
TLDR
Molecular-morphometric analysis of PTC can provide clonality information with potential clinical significance and, in PTC, subclonality for BRAF mutation is associated with earlier stage.
Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT.
TLDR
Multivariate analysis showed that TCs above 10% were the only significant factor for overall, tumor-specific, and relapse-free survival, and TERT promoter mutations are a strong predictor of tumor relapse, but their role as a surrogate marker for TCs is limited.
Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea.
Association between BRAFV600E mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma
TLDR
The results suggest that the BRAFV600E mutation is a risk factor for poor prognosis in patients with sPTMC.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.
TLDR
The results suggest that BRAF mutation in PTC is a later subclonal event, its intratumoral heterogeneity may hamper the efficacy of targeted pharmacotherapy, and its association with a more aggressive disease should be reevaluated.
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.
TLDR
The data suggest that BRAF V600E mutation is associated with high-risk PTC and in particular in follicular variant with invasive tumor growth.
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
TLDR
The BRAF(V600E) mutation was demonstrated to be a poor prognostic factor independent from other clinicopathological features in PTC patients, who were not only at a higher risk not to be cured but also for death.
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
TLDR
In patients with PTC, BRAF mutation is associated with poorer clinicopathological outcomes and independently predicts recurrence, and may be a useful molecular marker to assist in risk stratification for patients withPTC.
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
TLDR
The prevalence of B-RAF (V600E) is reported in the largest series of sporadic PTCs, including 260 cases from three different Italian referring centers, indicating that the prevalence of this genetic event lies around 38-40%.
Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA).
TLDR
MASA-PCR proved to be a specific, sensitive and reliable method to detect BRAF T1799A in DNA extracted from different sources, including cytologic samples obtained either fresh or from archival glass slides, and a useful tool to improve accuracy of preoperative diagnosis identifying PTC from biopsies with indeterminate cytologic findings.
The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
TLDR
In Korean patients with conventional micro-PTC, the presence of the BRAF(V600E) mutation was not significantly associated with prognostic factors.
Prognostic utility of BRAF mutation in papillary thyroid cancer
  • M. Xing
  • Medicine, Biology
    Molecular and Cellular Endocrinology
  • 2010
BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.
TLDR
There is no evidence that BRAF(V600E) mutation significantly reflects the aggressive characteristics and poor prognosis of patients with papillary carcinoma in Japan.
BRAFV599E Mutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas
TLDR
The molecular genetic study of the BRAF gene showed the presence of a missense thymine to adenine transversion at nucleotide 1796, resulting in the V599E substitution, in 24 of 60 PTCs (40%), none of six follicular adenomas, and none of five follicular carcinomas or one anaplastic carcinoma.
...
1
2
3
4
5
...